Skip to search formSkip to main contentSkip to account menu

Progesterone Agonist/Antagonist [EPC]

Known as: Mixed Progesterone Agonist and Antagonist, Progesterone Agonist/Antagonist, Selective Progesterone Receptor Modulator 
National Institutes of Health

Related topics

Related topics

1 relation
elective Progesterone Receptor Modulators [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
Objective The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM… 
2016
2016
Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
STUDY QUESTION Does administration of vilaprisan (VPR) to healthy women for 12 weeks reduce menstrual bleeding? SUMMARY ANSWER… 
Review
2015
Review
2015
Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
Uterine myoma is the most common benign uterine tumor in women of reproductive age and occurs in 20%–25% of the worldwide… 
2014
2014
Kaempferol Exhibits Progestogenic Effects in Ovariectomized Rats.
OBJECTIVE Progesterone (P4) plays a central role in women's health. Synthetic progestins are used clinically in hormone… 
2008
2008
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
The progesterone receptor plays an important role in the female reproductive system. Here we describe the discovery of a new… 
Highly Cited
2006
Highly Cited
2006
A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.
BACKGROUND This study was conducted to evaluate the effects of a novel selective progesterone receptor modulator (SPRM… 
Highly Cited
2005
Highly Cited
2005
The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women.
BACKGROUND Asoprisnil (J867) is a novel selective progesterone receptor modulator (SPRM) that exhibits partial agonist and… 
Review
2005
Review
2005
Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma.
Recent advances in endocrinology open a door for clinical application of selective estrogen receptor modulator (SERM) and… 
2004
2004
Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil
2004
2004
Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on selected hormonal parameters in subjects with leiomyomata
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)